KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–Jun. 18, 2024– KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of…Original Article